○Kayoko Saito1, Day John W2, Deconinck Nicolas3, Mazzone Elena S4, Nascimento Andres5, Oskoui Maryam6, Vuillerot Carole7, Braid Jessica8, Gerber Marianne9, Gorni Ksenija8, Martin Carmen8, Scalco Renata S9, Yeung Wai Yin8, Mercuri Eugenio4 (1.Institute of Medical Genetics, Tokyo Women's Medical University, Japan, 2.Department of Neurology, Stanford University, Palo Alto, CA, USA, 3.Neuromuscular Reference Center, UZ Gent, Ghent, Belgium, 4.Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy, 5.Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Deu, Fundacion Sant Joan de Deu, CIBERER - ISC III, Barcelona, Spain, 6.Departments of Pediatrics and Neurology Neurosurgery, McGill University, Montreal, Canada, 7.Department of Pediatric Physical Medicine and Rehabilitation, Hopital Mere Enfant, CHU-Lyon, Lyon, France, 8.Roche Products Ltd, Welwyn Garden City, UK, 9.F. Hoffmann-La Roche Ltd, Basel, Switzerland)
Session information
Oral Session
[O-35] Oral Session 35
Fri. May 20, 2022 9:45 AM - 11:15 AM Room13 (Tokyo International Forum G Block 5F G502)
Chair:Yasuo Ito(Department of Neurology, Saitama Medical University)
○Yasuhiro Takeshima1, Masson Riccardo2, Mazurkiewiczbeldzinska Maria3, Rose Kristy4, Servais Laurent5, Xiong Hui6, Zanoteli Edmar7, El-khairi Muna8, Gerber Marianne9, Gorni Ksenija9, Kletzl Heidemarie9, Dodman Angela9, Gaki Eleni8, Darras Basil T10 (1.Department of Paeditrics, Hyogo College of Medicine, Japan, 2.Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, 3.Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, 4.Department of Developmental Neurology, Medical University of Gdansk, Gdansk, Poland, 5.Paediatric Gait Analysis Service of New South Wales, The Children's Hospital at Westmead, Sydney, Australia, 6.I-Motion - Hopital Armand Trousseau, Paris, France, 7.Department of Pediatrics, Peking University First Hospital, Beijing, China, 8.Department of Neurology, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil;, 9.Roche Products Ltd, Welwyn Garden City, UK, 10.F. Hoffmann-La Roche Ltd, Basel, Switzerland)
○Hisaka Igarashi1, Mika Komori2, Krege John3, Baygani Simin K.3, Vincent Maurice3, Hauck Paula3, Macgregor Anne4 (1.Fujitsu Clinic, Kawasaki, Japan, 2.Eli Lilly K.K., Kobe, Japan, 3.Eli Lilly and Company, Indianapolis, USA, 4.Centre for Reproductive Medicine, St. Bartholomew's Hospital, London, UK)
○Yoshihisa Tatsuoka1, Mika Komori2, Yuka Tanji2, Akichika Ozeki2, Takao Takeshima3 (1.Tatsuoka Neurology Clinic, Kyoto, Japan, 2.Eli Lilly Japan K.K., 3.Tominaga Hospital, Osaka, Japan)
○Tomohide Adachi1, Thapar Manish2, Bonkovsky Herbert L3, Monroy Susana4, Ross Gayle5, Guillen-Navarro Encarna6, Cappellini Maria Domenica7, Minder Anna-Elisabeth8, Liu Shangbin9, Sweetser Marianne T9, Kuter David J10 (1.Department of Neurology and General Internal Medicine, Tokyo Saiseikai Central Hospital, Japan, 2.Massachusetts General Hospital, Boston, MA, USA, 3.Thomas Jefferson University, Philadelphia, PA, USA, 4.Wake Forest University/North Carolina Baptist Medical Center, Winston-Salem, NC, USA, 5.Instituto Nacional de Pediatria, Mexico City, Mexico, 6.Royal Melbourne Hospital, Melbourne, Victoria, Australia, 7.Medical Genetics Section, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain, and CIBERER-ISCIII, Madrid, Spain, 8.University of Milan, Milan, Italy, 9.Division of Endocrinology, Diabetes and Porphyria, Stadtspital Waid und Triemli, Zurich, Switzerland, 10.Alnylam Pharmaceuticals, Cambridge, MA, USA)
○Yasutaka Murakami1, Kenichi Todo1, Yasufumi Gon1, Shuhei Okazaki1, Tsutomu Sasaki1, Kazutaka Uchida2, Shinichi Yoshimura2, Takeshi Morimoto3, Hideki Mochizuki1 (1.Department of Neurology, Osaka University Graduate School of Medicine, Japan, 2.Department of Neurosurgery, Hyogo College of Medicine, 3.Department of Clinical Epidemiology, Hyogo College of Medicine)